Posted: 4 June 2025
INOVIQ Limited announced groundbreaking results from its EXO-OC™ ovarian cancer test at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2025, in Chicago. The test achieved 77% sensitivity and 99.6% specificity in detecting ovarian cancer across all stages, including early-stage I and II cancers, with no missed diagnoses. This test, utilizing proprietary technology to isolate exosomes and combining multiple exosomal biomarkers in an AI-enhanced algorithm, was presented in a poster titled “Early detection of ovarian cancer: An accurate high-throughput extracellular vesicle test.”
Since December 2024, INOVIQ collaborated with Prof Amanda Barnard to analyze miRNA biomarker data and develop AI machine-learning algorithms to enhance early-stage ovarian cancer detection. The test, run on a fully-automated, high-throughput instrument, processed over 500 samples daily in a 532-sample, retrospective, blinded, case-control study. An Australian Provisional Patent Application was filed on May 29, 2025, to secure intellectual property rights for the test.
Ovarian cancer, often asymptomatic in early stages, is typically diagnosed late, resulting in a 5-year survival rate of only 49%. Early detection could increase survival rates to 93%. The next steps include validation studies to confirm specificity, clinical studies for FDA approval, and commercialisation as a Laboratory Developed Test in the US, followed by broader clinical adoption as an In Vitro Diagnostic.
Prof Carlos Salomon highlighted the test’s potential to save lives by enabling earlier diagnosis and intervention. Dr Leearne Hinch emphasized INOVIQ’s position as a global leader in exosome technology, focusing on rapid commercialisation. Chairman David Williams noted the significant unmet need for a non-invasive, accurate ovarian cancer screening test.
The announcement was authorized by Company Secretary Mark Edwards. Further information was provided by Dr Leearne Hinch, CEO, and David Williams, Chairman. INOVIQ Ltd, a leader in exosome technology, is pioneering next-generation diagnostics and therapeutics to improve cancer patient outcomes.
For more information, click here.
